Navigation Links
EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States
Date:9/30/2009

ROCKLAND, Mass., Sept. 30 /PRNewswire/ -- EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS). Cladribine Tablets has the potential to be the first orally administered disease-modifying therapy available for people living with relapsing MS, as all disease-modifying therapies currently approved for the treatment of MS are parenteral therapies.

"As a leader in the area of neurodegenerative diseases, we continue to focus on making a positive difference in the lives of people living with MS, and their families," said Fereydoun Firouz, President and CEO of EMD Serono, Inc. "If approved, short-course therapy with Cladribine Tablets could transform the way people approach their treatment options, and meet an unmet need as an oral, disease modifying drug available for MS. We look forward to working with the FDA during the course of the regulatory process."

The NDA submission is supported by results from the CLARITY(a) study, a two-year, randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in people with relapsing-remitting MS. The NDA also shows that all primary and secondary endpoints of the CLARITY trial were met. The CLARITY data were presented at the 61st Annual Meeting of the American Academy of Neurology (AAN) in April 2009 and at other recent international scientific meetings.

(a) CLARITY: CLAdRIbine Tablets Treating MS OrallY

About the CLARITY study

The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled, international trial. It randomized 1,326 patients with relapsing-remitting MS according to the revised McDonald criter
'/>"/>

SOURCE EMD Serono, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
2. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
3. Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
4. Merck Seronos Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinsons Disease in a Phase III Pivotal Trial
5. Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
6. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
7. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
8. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
9. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
10. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
11. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... AUSTIN, Texas , March 30, 2015 ... highlight the My Diabetes Emergency Plan at the 2015 ... encourage you to be prepared to manage your #diabetes ... of Endocrinology (ACE) – the charitable, educational and scientific ... – has joined forces with Lilly Diabetes to share ...
(Date:3/30/2015)... , March 30, 2015  Check-Cap Ltd. (NASDAQ: ... focused on the development of a preparation-free ingestible imaging ... colorectal cancer, announced today that its CEO, Guy Neev ... 31, 2015 trading day.  Neev and Check-Cap will participate ... the company,s initial public offering and simultaneous private placement ...
(Date:3/30/2015)... March 30, 2015  Uroplasty, Inc. (NASDAQ: UPI ... shareholders have voted at the special meeting of ... previously announced agreement and plan of merger between ... with the outcome of today,s special meetings, and ... for approving the merger agreement," said Rob ...
Breaking Medicine Technology:Preparation Is Personal for Those with Chronic Illnesses 2Preparation Is Personal for Those with Chronic Illnesses 3Preparation Is Personal for Those with Chronic Illnesses 4Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 2Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 2Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 4
... Pa., May 25, 2011 A study titled ... published in the May 26 issue of ... prostate cancer who have received prior chemotherapy containing ... when treated with ZYTIGA ™ (abiraterone acetate) ...
... (NASDAQ: ITMN ) will outline the company,s corporate ... ongoing plans to commercialize Esbriet ® (pirfenidone) in Europe, ... pirfenidone study, during a meeting with analysts in New York ... the presentations beginning at 8:30 a.m. EDT.   ...
Cached Medicine Technology:Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate) 2Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate) 3Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate) 4Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate) 5Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate) 6InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study 2InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study 3InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study 4InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study 5InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study 6
(Date:3/30/2015)... Dr. Jeffrey Allred DDS, with his practice ... second opinion consultations for patients who need a ... dental second opinions show how small percentage of dentistry patients ... Only 6%” – says Dr. Allred. , “People should ... trusting the dental care provider, for the simple fact that ...
(Date:3/30/2015)... Birmingham, AL (PRWEB) March 30, 2015 ... medical malpractice and defective medical devices, has filed a ... Alabama family whose baby died following his premature birth ... Mobile County Circuit Court, alleges that the Mirena IUD ... strings, which also made the device difficult to remove. ...
(Date:3/30/2015)... 30, 2015 “ iCareTech ” was featured ... takes a look at the latest and coolest technology products ... reporter and technology expert, conducted the review and shared with ... dedicated to the medical and health fields. , Wearable technology ... over the past couple of years. Well, at CES, NewsWatch ...
(Date:3/30/2015)... According to a recently published report by iData ... continue to dominate the European soft tissue reinforcement and ... numbers of ventral hernias, and the adoption of expensive ... market share represented by ventral hernia repair devices is ... growing use of expensive biologics,” explains Dr. Kamran Zamanian, ...
(Date:3/30/2015)... March 30, 2015 Follow us ... efforts to develop and establish chronic pain rehabilitation centers ... in the market is poised to benefit from the ... of the increase in chronic health conditions such as ... arthritis, among others. While conventional treatment for pain management ...
Breaking Medicine News(10 mins):Health News:Allred Dental Offers Complimentary 15 Minute Consults with Dr. Jeffrey Allred in San Marcos, CA 2Health News:Mirena Lawsuit Filed By Southern Med Law Seeks Compensation For Purported Wrongful Death Following Premature Birth Of Infant 2Health News:Mirena Lawsuit Filed By Southern Med Law Seeks Compensation For Purported Wrongful Death Following Premature Birth Of Infant 3Health News:Mirena Lawsuit Filed By Southern Med Law Seeks Compensation For Purported Wrongful Death Following Premature Birth Of Infant 4Health News:World’s First Medical Intelligent Band was Featured on NewsWatch Television on January 30, 2015 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 3Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 3
... 19 Statement by Chris,Cathcart, President, CSPA: "The ... report issued by the Natural Resources,Defense Council (NRDC) ... air,freshener products. NRDC,s report appears to be based ... each of 14 air freshener products. As a,result, ...
... September, 2007 The decline in cervical ... there are reasons to be optimistic about even further ... women who are not screened. A meta-analysis by Spence ... Preventive Medicine shows that undergoing Pap smears irregularly or ...
... University School of Medicine (BUSM), Boston University School ... Lung and Blood Institute (NHLBI), have completed analyses ... two generations of participants from the landmark Framingham ... genetic differences that potentially affect the risk for ...
... peripheral artery disease , , WEDNESDAY, Sept. 19 (HealthDay ... tickling America,s funny bone and tugging at its ... working for now, crisscrossing the country to raise ... cardiovascular threat called peripheral artery disease (PAD). , ...
... Reserve Grand Champion Pair Of Cattle Comes From Binson,s ... Home Health Care Centers, Donation Of Food And Funds Continues Longstanding ... ... homeless and working poor will be among those to benefit from a,generous gift from Binson,s ...
... to end insurance ... pass S.558, ALEXANDRIA, Va., Sept. 18 Mental ... legislation,today to end mental health insurance discrimination, and its ... Edward,Kennedy (D-Mass.) for their leadership. The bill -- S. ...
Cached Medicine News:Health News:Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners 2Health News:Cervical cancer screening: Too many are left unprotected 2Health News:Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits 2Health News:Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits 3Health News:'Cosby' Star Tackles a Silent Heart Threat 2Health News:'Cosby' Star Tackles a Silent Heart Threat 3Health News:'Cosby' Star Tackles a Silent Heart Threat 4Health News:$8,000 Winning Bids at Governor's Livestock Auction to Benefit College-Bound Youth and Homeless 2Health News:Senate Passes 'Mental Health Parity' 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: